Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caribou Biosciences (CRBU) EBIT: 2019-2024

Historic EBIT for Caribou Biosciences (CRBU) over the last 6 years, with Dec 2024 value amounting to -$166.6 million.

  • Caribou Biosciences' EBIT rose 23.11% to -$29.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$158.8 million, marking a year-over-year increase of 3.88%. This contributed to the annual value of -$166.6 million for FY2024, which is 43.56% down from last year.
  • Latest data reveals that Caribou Biosciences reported EBIT of -$166.6 million as of FY2024, which was down 43.56% from -$116.1 million recorded in FY2023.
  • In the past 5 years, Caribou Biosciences' EBIT registered a high of -$36.1 million during FY2020, and its lowest value of -$166.6 million during FY2024.
  • Over the past 3 years, Caribou Biosciences' median EBIT value was -$116.1 million (recorded in 2023), while the average stood at -$129.7 million.
  • Data for Caribou Biosciences' EBIT shows a maximum YoY plummeted of 85.41% (in 2021) over the last 5 years.
  • Over the past 5 years, Caribou Biosciences' EBIT (Yearly) stood at -$36.1 million in 2020, then plummeted by 85.41% to -$67.0 million in 2021, then slumped by 58.85% to -$106.4 million in 2022, then dropped by 9.08% to -$116.1 million in 2023, then slumped by 43.56% to -$166.6 million in 2024.